Clinical Trial Update: Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating DWJ211 for efficacy and safety in patients with moderate to severe submental fat has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Submental Fat

Drugs mentioned

• DWJ211

Snippet

Sponsor: Daewoong Pharmaceutical Co. LTD. | Conditions: Submental Fat | Phase 3 | Status: COMPLETED